Áú8Ψһ¹ÙÍø

²úÆ·ÖÐÐÄ

ÁªÏµÁú8Ψһ¹ÙÍø

+86-010-82156767

ÏúÊÛרÓãº

+86-010-62983737 

+86-15522507305 

+86-15522507319 

+86-15522507326

µØµã£º±±¾©Êк£µíÇøÎ÷С¿Ú·66ºÅÖйش嶫Éý¿Æ¼¼Ô°C-1Â¥Èý²ã

undefined
+
  • undefined

Fmoc Amine PEG Amine, TFA Salt

²úÆ·´úºÅ£º

FMOC-PEG-NH2TFA

²úÆ·´¿¶È£º

¡Ý 95%

°ü×°¹æ¸ñ£º

1g, 10g, 100gµÈ£¨ÌØÊâ°ü×°ÐèÊÕÈ¡·Ö×°Óöȣ©

·Ö×ÓÁ¿£º

2000 Da,3500 Da, 5000 Da, 7500 DaµÈ

²úÆ·×Éѯ£º

¿ÆÑпͻ§Ð¡ÅúÁ¿Ò»¼ü²É¹ºµØµã£¨Ð¡ÓÚ5¿Ë£©

Á¢¼´Ïµ¥
  • ²úÆ·ÃèÊö
  • ²Î¿¼ÎÄÏ×

  • ¡¡¡¡Áú8Ψһ¹ÙÍø¿Æ¼¼Éú²úµÄÒìÜ̼×ÑõôÊ°±»ù¾ÛÒÒ¶þ´¼°·Èý·úÒÒËáÑβúÆ·Öк¬Óа·»ùÍż°Êܱ £»¤µÄ°·»ù £¬Í¨³£ÓÃ×÷Á½ÖÖ²î±ð»¯Ñ§ÎïÖʵĽ»Áª¼Á»ò¼ä¸ôÎï¡£´ËÒ칦ЧPEGÑÜÉúÎïÖеÄPEG²¿·Ö¿ÉÌṩˮÈÜÐÔ¡¢ÉúÎïÏàÈÝÐÔ¼°ÈáÐÔ¡£´Ë²úƷרÃÅÓ¦ÓÃÓÚ¿¹ÌåżÁªÒ©Îï(ADC¡¯s)µÄ¿ª·¢¡£

    ²úÆ·±àÂë

    ²úÆ·´úºÅ

    A5138

    FMOC-PEG2000-NH2TFA

    A5139

    FMOC-PEG3500-NH2TFA

    A5140

    FMOC-PEG5000-NH2TFA

    A5141

    FMOC-PEG7500-NH2TFA

    ¡¡¡¡Áú8Ψһ¹ÙÍø¿Æ¼¼ÌṩFMOC-PEG-NH2TFA·Ö×ÓÁ¿2000 Da,3500 Da, 5000 Da, 7500 DaµÄ²úÆ·1¿ËºÍ10¿Ë°ü×°¡£

    ¡¡¡¡Áú8Ψһ¹ÙÍø¿Æ¼¼Ìṩ·ÖװЧÀÍ £¬ÐèÒªÊÕÈ¡·Ö×°ÓöÈ £¬Èç¹ûÄúÐèÒª·ÖװΪÆäËû¹æ¸ñÇëÓëÎÒÃÇÁªÏµ¡£

    ¡¡¡¡Áú8Ψһ¹ÙÍø¿Æ¼¼Í¬Ê±ÌṩÆäËû·Ö×ÓÁ¿µÄFMOC-PEG-NH2TFAÑÜÉúÎï²úÆ· £¬ÈçÄãÐèÒªÇëÓëÎÒ˾sales@jenkem.comÁªÏµ¡£

    ¡¡¡¡Áú8Ψһ¹ÙÍø¿Æ¼¼Ìṩ´óÅúÁ¿Éú²ú²úÆ·¼°GMP¼¶±ð²úÆ· £¬ÈçÐ豨¼ÛÇëÓëÎÒÃÇÁªÏµ¡£

     

  • ¡¡¡¡References:

    ¡¡¡¡1. Soni, K.S., et al., Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer, Journal of Controlled Release, 2017, V. 264, P. 276-287.

    ¡¡¡¡2. Kim, H.C., et al., Folic Acid-Functionalized Polythiophene for Targeted Cellular Imaging, Journal of Nanoscience and Nanotechnology, 2016, 16:1, p. 189-195(7).

    ¡¡¡¡3. Fahrländer E., et al., PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent, Nanotechnology, 2015, 26(14):145103.

    ¡¡¡¡4. Desale, S.S., et al., Targeted delivery of platinum-taxane combination therapy in ovarian cancer, Journal of Controlled Release, 2015, 220B, P. 651-659.

²úƷѯ¼Û

ÍøÕ¾µØͼ